About Immutopics
Immutopics is a Healthcare company based in San Clemente (United States) founded in 1989, and was acquired by Quidel in March 2016. Immunoassays for bone health assessment are developed and marketed. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Diversified. Its competitors include GenScript, OriGene and Meridian Bioscience; 2 of its 3 listed competitors have raised funding.
Company details
Immutopics develops, manufactures and markets immunoassays for assessing bone health to the research and scientific communities. Its product line includes ELISA kit for the determination of Human fibroblast Growth Factor-23 levels in plasma or cell culture media, ELISA kit for quantitative determination of Human Intact FGF-23 levels, ELISA kit for Human Bioactive Intact PTH levels, ELISA kit for quantitative determination of Human parathyroid hormone 1-34 levels, and ELISA kit for detection of Anti-Human PTH (1-34) antibodies in Serum, Plasma or Cell culture media. The company got acquired by Diagnostic Hybrids, Inc., a wholly owned subsidiary of Quidel Corporation, on March 18, 2016.
- Headquarters San Clemente, United States
- Stage Acquired
- SectorsHealthcare
- Website immutopics.com
- Acquired by Quidel (Mar 2016)
- Investors
- Acquired byQuidel
(Mar 2016)
Investors in Immutopics
Immutopics has secured backing from 1 investor. Prominent investors backing the company include QuidelOrtho.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
QuidelOrtho is engaged in providing diagnostic testing solutions globally. | quidel.com | San Diego, United States |
Investor details for Immutopics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Immutopics
2 dated milestones of Immutopics across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Immutopics is founded.
- Exit Acquired by Quidel.
Competitors of Immutopics
Immutopics has 3 listed competitors in our database, 2 of them funded. They include GenScript, OriGene and Meridian Bioscience.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| origene.com | 1996 | Rockville, United States | $69.55M | 141 | Proteins, antibodies, and molecular tools are manufactured for research applications. | |
| meridianbioscience.com | 1976 | Ohio, United States | Molecular diagnostic device and kits |
Detailed competitors of Immutopics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Immutopics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Immutopics
Immutopics was founded in 1989.
Immutopics is headquartered in San Clemente, United States. It is registered at San Clemente, California, United States.
Immutopics develops, manufactures and markets immunoassays for assessing bone health to the research and scientific communities. Its product line includes ELISA kit for the determination of Human fibroblast Growth Factor-23 levels in plasma or cell culture media, ELISA kit for quantitative determination of Human Intact FGF-23 levels, ELISA kit for Human Bioactive Intact PTH levels, ELISA kit for quantitative determination of Human parathyroid hormone 1-34 levels, and ELISA kit for detection of Anti-Human PTH (1-34) antibodies in Serum, Plasma or Cell culture media. The company got acquired by Diagnostic Hybrids, Inc., a wholly owned subsidiary of Quidel Corporation, on March 18, 2016.
Immutopics's top competitors include Meridian Bioscience, GenScript and OriGene.
Immutopics has 1 investor. Key investors include QuidelOrtho.
Yes. Immutopics was acquired by Quidel in March 2016.